CD19 and lymphoma: A higher CD4:CD8 T-cell ratio utilized at the pre-transduction and expansion stage was associated with greater in vivo BCMA-targeted CAR T-cell expansion and response74, corroborating the reports in the CD19-targeted CAR T-cell therapy in lymphoma and ALL80,81.